2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Omics Technologies, Treatment Considerations, Biological Therapies, Infusion, Non-Biological Therapies, Anticoagulant Drugs, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality of Care, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Genetic Disorders, Lymphoid Malignancies, Lymphomas, Research, Clinical Research, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly
PAPER

3086 Thrombotic events in pediatric hypereosinophilic syndrome: A single-center retrospective cohort study

Brandon Lucari, MD, Joud Hajjar, MD, PhD, MS2, Oluwaseun Kemi O Olaiya, DO3
1 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
2 Baylor College of Medicine, Houston, Texas, United States, Center for Human Immunobiology, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States
3 Baylor College of Medicine, Houston, Texas, United States, Texas Children's Hospital, Houston, Texas, United States

Introduction Hypereosinophilic syndromes (HES) are defined as persistent eosinophilia with organ involvement resulting in tissue injury. In adult patients with HES the rate of thromboembolic events is well described, occurring in up to 25% of patients, contributing to increased mortality. In contrast, pediatric data are limited. Although HE prevalence in children is estimated at 31.4 per 100,000, no studies have reported thrombosis incidence or antithrombotic (including anticoagulant and antiplatelet) management in pediatric HES. Whether HES related eosinophilia or tissue infiltration confers a similar thrombotic risk in children remains unknown. To address this gap, we conducted a retrospective review at a large tertiary pediatric center. This is the first cohort level description of thrombosis and real-world antithrombotic practices in pediatric HES.

Methods We reviewed pediatric patients aged 0–18 years diagnosed with HES at Texas Children’s Hospital between January 1, 2000, and January 1, 2025. Data were abstracted from the electronic medical record, and diagnoses were confirmed by pediatric Hematology or Allergy/Immunology physician. Patients were stratified by thrombosis and receipt of antithrombotic therapy. Continuous variables are reported as medians with interquartile ranges, categorical variables as frequencies and proportions. Peak AEC was compared using the Mann–Whitney U test due to non-normal distribution. A two-tailed alpha of 0.05 was used.

Results Twenty-four patients were identified (12 male, 12 female), median age 10.1 years (IQR 5.8-15.0) with a median follow up of 43.2 months (IQR 23.2-65.8 months). 75% had idiopathic HES (n=18), with the remainder diagnosed with lymphocytic-variant (25% n=6). Genetic testing was performed in 83% (n=19) with no molecular aberrations identified. One patient (4%) died during follow-up. 12.5% (n=3) of patients had a documented history of thrombosis, though only one patient (4.2%) was considered to be eosinophil mediated through tricuspid valve infiltration with secondary mitral valve thrombosis (peak AEC 13,570 cells/µL). This patient received IV glucocorticoids, mepolizumab, aspirin, and therapeutic enoxaparin for 3.8 months until thrombus resolution. The remaining two patients with thrombotic events had occurred prior to onset of eosinophilia and were likely secondary to surgical procedures in both these patients with congenital heart disease. 

Antithrombotic therapy was used in 8/24 patients (33%). 8% (n=2) received anticoagulation (enoxaparin, heparin, bivalirudin, rivaroxaban), 8% (n=2) received aspirin, and 17% (n=4) received dual therapy. Minor bleeding events occurred in patients on aspirin: two patients had mild mucosal bleeding, and one had mild hemoptysis attributed to pulmonary eosinophilia. In the patients receiving antithrombic therapy 50% (n=3) were for prophylaxis. Indications included elevated AEC (n=1) or eosinophilic myocarditis (n=2). 100% (n=8) of HES patients on anticoagulation were also on targeted HES therapy with mepolizumab for IL-5 inhibition compared to 25% (n=4; p=0.001) in the non-antithrombotic therapy group. Peak AEC did not differ between antithrombotic and non-antithrombotic groups (median 4,285 vs 3,589 cells/µL; p=0.697). Antithrombotic therapy was primarily used in patients with cardiac disease. Treated patients were more likely to have severe congenital heart disease (38% vs 0%; p=0.028), prior heart transplantation (38% vs 0%; p=0.028), and HES-associated myocarditis (50% vs 6%; p=0.028).

Conclusion In this first pediatric cohort evaluating thrombosis and antithrombotic management in HES, we observed an HES mediated thrombosis incidence of 4.2%. Thrombosis rates were lower than those reported in adults, suggesting important age-related differences in disease phenotype. Cardiac involvement rather than eosinophil burden was the primary factor prompting prophylactic anticoagulation. One-third of patients received antithrombotic therapy, which appeared safe with no major drug-related bleeding. No molecular aberrations were identified, contrasting with adult HES where genetic drivers such as PDGFRA are linked to increased thrombotic risk. IL-5 directed therapy was used in all children receiving antithrombotic treatment, reflecting greater disease severity in this subgroup. Prospective multicenter studies are needed to define optimal thrombosis prophylaxis in pediatric HES, particularly for patients with cardiac involvement. 

 

 

Brandon Lucari, MD: No relevant conflicts of interest to declare.